Compare SoFi Technologies Inc (SOFI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? SoFi Technologies Inc trades at $15.77 (market cap $20.16B), while Zimmer Biomet Holdings Inc trades at $89.61 (market cap $16.95B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SOFI | ZBH | |
|---|---|---|
Market Cap | $20.16B | $16.95B |
Volume | 49,646,331 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $32.21 | $103.98 |
52-Week Low | $15.15 | $79.58 |
Typical Hold Time | 60 Days | 89 Days |
Enterprise Value | $20.30B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies (SOFI) trades at $15.66, down 0.64% on the day and near its 52-week low, reflecting bearish technical signals. The company reported strong revenue growth to $3.61 billion in 2025 with a net income of $481.32 million, but negative operating cash flow and high leverage remain concerns. Analyst sentiment is mixed with a consensus price target of $21.58, implying significant upside, while recent news highlights growth in loan originations and stablecoin initiatives.
The outlook for SOFI hinges on sustaining profitability amid competitive pressures and interest rate sensitivity. Upside potential exists from execution on guidance and market share gains, but risks include persistent cash burn and macroeconomic headwinds. Investors should weigh the growth trajectory against valuation premiums and operational challenges.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
